Jasper Therapeutics reported third-quarter 2025 results and a corporate update centered on briquilimab, its anti-KIT antibody in chronic urticaria...

Kamada reported third-quarter 2025 revenues of $47.0 million, up 13% year over year, with adjusted EBITDA up 34% to...

Tenaya Therapeutics reported new clinical signals from its cardiac gene therapy programs while navigating a temporary FDA clinical hold...

uniQure reported pivotal 36-month data for AMT-130 in Huntington’s disease that met its primary and key secondary endpoints, using...

Septerna outlined a pivotal quarter: a new oral PTH1R agonist, SEP-479, has been selected as the development candidate for...

Editas Medicine has named EDIT-401 as its lead in vivo gene editing program for LDL cholesterol reduction, reported non‑human...

ARS Pharmaceuticals reported $32.5 million in third-quarter 2025 revenue, driven by $31.3 million in U.S. net product sales of...

Pharvaris used ACAAI 2025 to consolidate the clinical story for its oral bradykinin B2 antagonist deucrictibant across both prophylaxis...

I’ve been asking myself a question that’s almost heretical in this industry. Could biotechs ever be free of Big...

CytomX reported third-quarter 2025 results and a focused clinical cadence: a Phase 1 data update for its first-in-class EpCAM-directed,...